Mahidol University Preclinical (Lab) Studies Indicate Potential of Ivermectin/Niclosamide Combination as Antiviral Targeting COVID-19

Mahidol University Preclinical (Lab) Studies Indicate Potential of Ivermectin/Niclosamide Combination as Antiviral Targeting COVID-19

Recently, a team of scientists affiliated with Thailand-based academic medical centers, including Mahidol University’s Siriraj Hospital, investigated the use of repurposed antiparasitic drugs with in vitro anti-SARS-CoV-2 activity, as this continues to represent a promising approach for economical, available antiviral-like treatments targeting COVID-19. Of particular importance is the ability to alleviate stress on healthcare systems, especially in more vulnerable low-and middle-income countries (LMICs) such as Thailand. The recent study acknowledges the limitations of the global mass vaccination scheme as a strategy to eradicate COVID-19—the pathogen continues to spread whether in 100% vaccinated locations such as Gibraltar, to nearly universally vaccinated Singapore. Thus, the importance of utilizing safe and effective, not to mention economical antiviral-like treatments, as a public health strategy, as well as augmenting vaccination and other measures. Novel pharmaceutical products from companies such as Merk and Pfizer, while showing some promise, also present possible safety and cost issues. Thus, the team out of Mahidol University sought to test repurposed drugs in...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee